Third Harmonic Bio

Clinical-stage company developing a first-in-class, highly selective, oral KIT inhibitor for treatment of severe allergy and inflammation. Learn more

Launch date

2019

Employees

Market cap

Enterprise valuation

€278m (Public information from Sep 2024)

Cambridge Massachusetts (HQ)

https://thirdharmonicbio.com/

https://twitter.com/3rdharmonicbio https://www.linkedin.com/company/third-harmonic-bio/

Authorizing premium user...